Page 28 - Phase 3 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The Latest: UK says variant could delay ending restrictions The Associated Press FacebookTwitterEmail 14 1of14Traffic is controlled at a COVID-19 testing facility in Melbourne, Australia, Thursday, May 27, 2021, Australia’s second largest city announced a seven-day lockdown on Thursday as concern grows over dozens of cases of a COVID-19 variant found in India. (James Ross/AAP Image via AP)James Ross/APShow MoreShow Less 2of14A customer wearing a protective mask to help curb the spread of the coronavirus orders medicine through plastic sheets in front of drug store in Bangkok, Th...

PARIS (AP) — Production of another potential vaccine against COVID-19 will begin within...

Are only getting pfizer. how big of a deal will it be if moderna gets approved as well? >> now we'll have both moderna and pfizer vaccine for adolescents. they were both 100% protective. it's a small sampling compared to the earlier phase 3 trial. so the 100% will probably not hold up but it's still very, very high. high levels of protections and antibodies, at least for the pfizer vaccine, so it's a good vaccine. what that means is if we can get a significant percentage of both adults and adolescents immunized by the fall, middle schools and high schools will be safe and elementary schools wi...

WEST LAFAYETTE, Ind., May 20, 2021 /PRNewswire/ -- On Target Laboratories, Inc., a privately held biotechnology company developing fluorescent markers to target and illuminate cancer during surgery, today announced results of the 006 Study, a Phase 3, randomized, multi-center, prospective, open-label study to investigate the safety and efficacy of pafolacianine sodium injection (OTL38) for intraoperative imaging of folate receptor positive ovarian cancer. In 33% of patients (36 of 109), near-infrared imaging with pafolacianine sodium injection identified additional lesions which would have be...

Optimus Pharma gets nod for phase 3 trials of Molnupiravir capsule Updated: Updated: Share Article AAA Drug-maker Optimus Pharma on Wednesday said it received approval of the Drugs Controller General of India (DCGI) to conduct Phase III clinical trials for Molnupiravir capsule on mild and moderate COVID-19 patients. As per the clinical trial protocols approved, a total of 2,500 subjects in both mild and moderate COVID-19 will be randomised in the study in a 1:1 ratio to Molnupiravir with standard supportive care or standalone standard supportive care. The treatment duration is a maximum of ...